Cellular functions of tumor suppressor proteins can be mediated by protein-protein interactions. Using p53 as a probe to screen an expression library, a cDNA encoding a 250 kDa protein was isolated. Recombinant forms of this protein, designated PACT, bind to wild type p53 while two dierent mutations abolish this interaction. PACT protein can also interfere with p53 speci®c DNA binding. PACT contains a serine/arginine (SR) rich region and a C' terminal lysine rich domain. The 250 kDa PACT protein can be precipitated from cell lysates by a method speci®c for SR proteins. snRNPs can be co-immunoprecipitated from cells with anti-PACT antibodies. These antibodies stain cell nuclei in a speckled pattern reminiscent of the distribution of known splicing factors. Recently, RBQ1, a truncated human homologue of PACT was identi®ed by virtue of Rb binding. We show that RBQ1 is truncated as a result of a possible mutational event. PACT can interact with both cellular Rb and p53.
Introduction
Elucidation of p53 and Rb protein-protein interactions with both viral and cellular proteins, has shed light on various functions of these proteins. Binding of p53 and Rb to transforming proteins from several DNA tumor viruses can cause functional inactivation of these tumor suppressor proteins (p53: Lane et al., 1979; Linzer et al., 1979; Sarnow et al., 1982; Werness et al., 1990; Szekely et al., 1993; Wang et al., 1994; Rb: DeCaprio et al., 1988; Whyte et al., 1988; Dyson et al., 1989) . Both proteins act as cell cycle checkpoint components; p53 in G 1 (Deppert et al., 1990; Michalovitz et al., 1990; Mercer et al., 1990; Diller et al., 1990; Martinez et al., 1991; Ginsberg et al., 1991; Shaulsky et al., 1991) and in G 2 (Aloni-Grinstein et al., 1993; Stewart et al., 1994) and underphosphorylated Rb in G 1 (Chen et al., 1989; DeCaprio et al., 1989; Buchkovich et al., 1989) . One scenario for a physiological interrelationship between Rb and p53 is that p53 transcriptionally induces the expression of p21 WAF/CIP1 (El-Deiry et al., 1993; Harper et al., 1993) , a cyclin-dependent kinase inhibitor. This prevents phosphorylation of Rb at the G 1 /S transition, inhibiting E2F transcriptional activity and cell cycle progression (Chellappan et al., 1991; Weinberg, 1995) .
Several cellular proteins can interact with p53. Among them are mdm2 Barak et al., 1993) , WT1 (Maheswaran et al., 1993) , RPA (Dutta et al., 1993) , hsc70 (Hinds et al., 1987) , TBP (Seto et al., 1992) , spot-1 , and two proteins identi®ed by the two hybrid system (53BP1 and 2: Iwabuchi et al., 1994) . One cellular protein-protein interaction, involving mdm2, has a negative eect on the transcriptional activity of p53 Barak et al., 1993) . This interaction involves a feedback loop whereby p53 can induce transcription of the mdm2 gene. Recent results using knockout mice combinations, show that the lethality of mdm2 de®cient mice can be aborted by crossing mice with p53 knockout mice (de Oca Luna et al., 1995; Jones et al., 1995) . This ®nding shows that regulation of p53 by interaction with cellular proteins in vivo, is critical. However, transcriptional activity is only one aspect of cellular functioning since p53 can induce apoptosis (reviewed in White, 1996) , even when cellular transcription is absent (Caelles et al., 1994) . Also some mutated p53 proteins can support wild type transcriptional levels, but lack the ability to suppress growth (Marston et al., 1994; .
Other protein-protein interactions involving p53, point to a role in DNA replication. Binding of p53 to SV40 large T antigen can block the ability of T antigen to unwind the viral origin of replication (StuÈ rzbecher et al., 1988; Friedman et al., 1990) . p53 also has a direct inhibitory eect on large T and E coli helicase II DNA unwinding activities (Oberosler et al., 1993) . The acidic N' terminus of p53 can in¯uence in vitro replication assays and can bind replication factor A (RPA) (Li et al., 1993) . RPA is an essential component of cellular DNA replication and binding of p53 can inhibit RPA's ability to function (Dutta et al., 1993) .
Since protein-protein interactions appear to be central in p53 cellular activities, we set out to identify cellular proteins that may interact with p53. We assumed that application of a methodology that has not been used before in the study of p53, may help identify novel protein-protein interactions. Puri®ed wild type (wt) p53 protein was used as a probe on a mouse testes expression library. A cDNA encoding a novel nuclear protein was isolated. The protein, designated as PACT (P53 Associated Cellular protein-Testes derived), contains a serine/arginine (SR) rich region and a very basic lysine rich C' terminus. Recombinant PACT protein binds p53 in the wt conformation, but not mutated forms, and can compete for p53 speci®c DNA binding. Cellular PACT can only be visualized followig acetylation in vitro, and appears as a 250 kDa protein. A truncated human form was recently cloned using a similar assay, but the probe used in this case, was the Rb protein (Sakai et al., 1995) . We show that the 250 kDa PACT protein interacts with both cellular p53 and Rb. With the aid of anti-PACT antibodies we show that PACT localizes to nuclear speckles, where several splicing factors including the Sm antigens (Steitz et al., 1988) are localized (Spector, 1993) , and is associated with Sm antigens in nuclear extracts.
Results

Cloning of a p53 binding protein from a mouse testes expression library
In order to identify cellular proteins that can interact with p53, we partially puri®ed a bacterially expressed wt p53 protein (Shohat-Foord et al., 1991) . Soluble p53 was immunoanity puri®ed on a column of covalently bound PAb-421 antibody (see Materials and methods). The partially puri®ed protein was then radiolabeled by Na[ 125 I] and used as a probe on ®lters containing 1610 6 induced plaques from an adult mouse testes expression library cloned into lgt11. The integrity of the p53 protein was con®rmed by immunoprecipitating the radiolabelled probe directly from the hybridization uid (data not shown).
A single plaque that consistently bound the p53 probe was plaque puri®ed. The insert of this plaque was used as a probe on a Northern blot of total RNA from various mouse tissues (Figure 1a) . Expression of a 6.5 kb band could be detected in all tissues examined. However, the expression was highest in the testes. Initial sequencing of the insert from this plaque revealed a previously unknown open reading frame (ORF) which we termed PACT. In order to clone the entire sequence, we used the cDNA inserts as probes on the original library and another murine testes library. We cloned and sequenced 5177 bp of cDNA coding for 1583 amino acids (aa) and a 437 bp 3' noncoding region with a poly-A signal and tail. We also veri®ed that the sequence was contiguous by Northern analysis using cDNA probes from various regions of the sequence, including the non-coding 3' (Figure 1b) . All probes hybridized to the same band. Figure 2a shows the predicted aa sequence of PACT. A putative 34 aa alternatively spliced region is included (boxed area; aa 446 ± 479) that was identi®ed on some clones but not on others. Immediately adjacent to this area is a region with serine/arginine di-amino acid repeats (single underlined; aa 475 ± 566). This sequence is reminiscent of proteins of the SR splicing-related family of proteins (reviewed in Fu, 1995) . Another region of interest is a 54 aa sequence, directly adjacent to the stop codon, (double underlined; aa 1520 ± 1577) that encodes 31 lysine residues, including ®ve KKH repeats. The overall putative protein is highly charged with 22.5% basic residues and 14.3% acidic residues. However, by itself, the lysine rich area at the C' terminus has more than 68% basic residues, making it unusually charged.
A human homologue of PACT was cloned using the Rb protein and is a truncated form of PACT Recently, a human sequence, RBQ1, was identi®ed from a human small cell lung carcinoma (H69c) library, that is highly homologous to PACT (Sakai et al., 1995) . The strategy used to isolate RBQ1 was similar to ours, but the probe used was the Rb protein. This sequence predicts a much shorter version of the protein (948 aa), but continues 182 bp upstream to our most 5'-sequence, coding for an extra 30 aa up to a putative initiating methionine. We have not yet been able to clone the analogous murine 5' sequence. Figure  2b shows a graphic alignment of the mouse and human sequences.
The RBQ1 ORF encodes a stop codon (TAA) corresponding to position 919 aa of PACT. This TAA is present in PACT, but is out of frame because of an extra two nucleotides in PACT. There is a C at position 2526 bp and an A at position 2674 bp in PACT, that are absent in the RBQ1 sequence. Figure  2c shows an alignment of the PACT DNA sequence with RBQ1 and an EST fragment, cloned from a normal human retina library, and obtained from the dbEST databank (accession no. R85735). Both nucleotides are present in the EST sequence, as they are in the PACT sequence. These two nucleotides are present in other EST fragments that were cloned from normal human tissues (data not shown). We concluded, from this comparison to normal human sequences, that the sequence obtained from the H69c cell line library may be truncated as a result of a mutational event in this small cell lung carcinoma. The overall aa homology between PACT and RBQ1, within the overlapping 843 aa sequence, is 94%. The homology is 97% from the N' terminus up to the end of the SR region. This suggests that the two proteins are highly conserved and that the area of the SR region, including the 34 aa alternatively spliced domain, may be of functional signi®cance.
Recombinant PACT can bind wild type but not mutant forms of recombinant p53
In order to determine the properties of the PACT interaction with p53, we produced a recombinant PACT protein containing a C' terminal 66 His Tag using the pET 20b vector. This construct encodes for the 1147 aa of the C' terminal part of PACT. The bacterially expressed protein was puri®ed (see Materials and methods), and incubated with puri®ed mouse wt and mutant (codon 270 arg?cys) p53 proteins produced in the baculovirus system. Complexes were gathered on nickel Sepharose. Since any protein containing histidine residues can bind to the nickel Sepharose, complexes were repeatedly washed with a high salt buer containing 40 mM imidazole. Only proteins containing consecutive histidine repeats remain bound to the nickel Sepharose under these conditions, together with any proteins that are complexed with them.
After resolution of bound proteins on SDS ± PAGE, immunoblot analysis with anti-p53 antibodies ( Figure  3 ) revealed that the wt p53 could form a complex with PACT, while the mutant form could not. Almost all of the input wt p53 was found complexed to PACT. Similar results were also observed using wt p53 and a dierent mutant (M11; Wolf et al., 1985) produced in the pET bacterial system (data not shown).
PACT interferes with p53 DNA binding
In order to further establish and characterize the interaction of PACT and p53 proteins, we determined the eect of PACT on p53 DNA binding. Figure 4 shows gel retardation analysis using the p53 speci®c DNA binding oligonucleotide, 0.5 mg of recombinant wt p53 and increasing amounts of C' terminal PACT-GST fusion protein (aa 1220 ± 1562) or GST protein.
It has been established that the ability of p53 to bind its speci®c DNA binding site can be greatly facilitated by using the PAb-421 antibody, which is directed against a C' terminal epitope in p53 (aa 370 ± 378) (Hupp et al., 1992 (Hupp et al., , 1993 Funk et al., 1992) . In the 
Ni-NTA Figure 3 In vitro binding of PACT to p53 and Rb. Binding with p53. 0.5 mg of puri®ed bacculovirus wt or mutant (mut) p53 were incubated with 0.5 mg PACT-His Tagged recombinant protein (aa 436 ± 1584) for 15 min at 308C. The resulting protein complexes were gathered on nickel sepharose (Ni-NTA), followed by three washes with 40 mM imidazole to wash non-speci®c binding of histidine containing proteins to beads. After separation on SDS ± PAGE, the proteins were subjected to immunoblotting and detection with PAb-421. As controls, wt p53, mutant p53, or PACT, were incubated with nickel sepharose alone (lanes 1, 2 and 3, respectively). p53 in the wt conformation could bind PACT (lane 4) while mutated p53 could not (lane 5). 0.5 mg of wt p53 and mut p53 were also loaded directly in lanes 6 and 7, respectively p53 and Rb bind PACT, a SR protein A Simons et al presence of PAb-421, p53 could bind and retard migration of the DNA. When increasing amounts of PACT ± GST were added into the reactions, the DNA binding was decreased, while equal amounts of GST protein did not in¯uence this binding. As little as 1.2 mg of PACT ± GST competed for the DNA binding activity of p53 and this binding was almost totally abolished with 3.6 mg of PACT ± GST. PACT ± GST had no DNA binding activity in this assay.
Identi®cation of the cellular PACT protein
Polyclonal antibodies against PACT were raised in rabbits by immunization with puri®ed GST or His Tagged fusion proteins, encoded by three separate regions of the ORF. Figure 5a shows the pattern of immuno¯uorescent staining using one of these antibodies, Ab1, to stain Balb/C 3T3 ®broblasts. The same pattern was observed when cells were stained with Ab2 and Ab3 (data not shown), but not with pre-immune serum ( Figure 5b ). Also, the same pattern was observed in many cell lines stained with the three antibodies (data not shown). This nuclear speckled pattern is typical to the staining patterns of several known antibodies against splicing factors (e.g., U snRNPs and SR proteins) (reviewed in Spector, 1993) . Although these antibodies could recognize recombinant PACT proteins and consistently recognized the same pattern in immuno¯uorescent staining, we experienced diculties in speci®c recognition of a cellular protein(s) in SDS ± PAGE. We suspected that the very basic charge centered at the C' terminus was interfering with the migration of PACT on gels. In order to clarify this point, we utilized an in vitro acetylation reaction (Bayer EA, Ehrlich-Rogozinski S and Wilchek M, unpublished procedure). The aim of this chemical modi®cation was to neutralize the positive charge at the C' terminus, and throughout the protein, ensuring that (1) the positively charged PACT protein enters SDS ± PAGE gels and (2) antibodies may then interact with PACT protein through conformational recognition and not through charge recognition. In Figure 6a we demonstrate that upon acetylation of nuclear extracts and Western blot analysis, a single band of around 250 kDa was recognized by all three antibodies. This protein was absent without acetylation ( Figure 6b ). p250 probably does not migrate into SDS gels without acetylation. The recognition of a single band in Westerns, plus the identical immuno¯uorescent staining by all three antibodies suggests that p250
PACT is indeed the protein encoded for by the original cDNA. This protein is present in many cell lines that were examined, whether of human or murine origin (Figure 6b and  c) .
Interestingly, the H69c cell line had an additional 200 kDa protein that was not sensitive to acetylation (Figure 6c ). The antibodies recognized this protein even when not acetylated. This smaller protein is present also in the cytoplasmic compartment, whereas the 250 kDa PACT protein is entirely nuclear in HeLa (Figure 6c ) and other cell lines examined. This ®nding is complementary with the sequence information pointing to a mutational event in this cell, that causes the production of a truncated protein lacking the C' terminal portion (Figure 2c) . This protein would then be insensitive to the eects in gel migration observed after in vitro acetylation. Immunoblot analysis of cellular PACT in vivo. (a) A 250 kDa protein is recognized by three polyclonal antibodies raised against dierent PACT recombinant proteins. 50 mg/lane of D122 nuclear extract was subjected to in vitro acetylation, resolved on SDS ± PAGE, transferred to nitrocellulose and strips were subjected to immunoblot analysis with Ab1, Ab2, Ab3 or pre-immune serum as indicated. (b) p250 PACT is present in both murine and human cell lines, and can be visualized on SDS ± PAGE only after acetylation. 50 mg/lane of D122, 70/Z or HeLa nuclear extracts were subjected to immunoblot analysis with Ab2 as in (a), except that extracts in lanes 1, 3 and 5 were not acetylated. (c) H69c cells contain a 200 kDa protein that is recognized by anti-PACT antibodies, is cytoplasmic as well as nuclear, and is insensitive to acetylation. 50 mg/lane of either H69c or HeLa S100 cytoplasmic or nuclear extracts were subjected to immunoblot analysis with Ab2 as in (a). Extracts in lanes 1, 3, 5 and 7 were not acetylated p250
PACT can interact with cellular p53 and Rb proteins
In the experiment shown in Figure 7a and b, we tested whether p250
PACT could be co-immunoprecipitated directly from 35 S-labeled D122 nuclear extracts together with p53. Following immunoprecipitation with the designated antibodies, immune complexes were separated on SDS ± PAGE, with or without prior acetylation. Immunoblot analysis using anti-PACT antibodies (Figure 7a ) revealed that two anti-PACT polyclonal antibodies could speci®cally immunoprecipitate p250 PACT . Anti-p53 monoclonal antibodies PAb-248 and PAb-421 could also co-immunoprecipitate p250 PACT , while non-speci®c rabbit polyclonal or mouse serums could not. Because the amount of p250
PACT present in the PAb-248 reaction was much lower than in other reactions, this reaction is shown in an over-exposed version of the same blot (Figure 7a,  lanes 1 and 2) . The presence or absence of p53 protein in the reactions was veri®ed by exposing the nitrocellulose to X-ray ®lm to detect 35 S-labeled proteins (Figure 7b ). This is necessary since p53 comigrates with the heavy chain of Ig and is, thus, not detectable in immunoblots. p53 was present in the PAb-248 and PAb-421 reactions, but was not detected in anti-PACT immunocomplexes, suggesting that there may be steric hindrances with anti-PACT antibodies. The slightly larger form of p53 in the acetylated reactions is due to the covalent addition of acetyl groups to the protein.
Next, we tried to determine whether Rb could be coimmunoprecipitated together with p250
PACT and p53, from D122 nuclear extracts. A similar experiment to the one described above was carried out, except that the immunoblot analysis was done with anti-Rb antibodies (Figure 7c) . Surprisingly, p105
Rb was present in reactions carried out with Ab2 and Ab3 anti-PACT antibodies and also with the PAb-421 and PAb-248 antibodies, but not with Ab1 and non-speci®c rabbit and mouse serums (Figure 7c) . A lane containing unfractionated nuclear lysate shows the total amount of Rb protein which appears to be present mainly in the under-phosphorylated form in these cells. Only a small fraction of the total Rb was present in the PACT and p53 immunocomplexes. The fact that Rb was present in immunocomplexes together with p53 may be interpreted as a simultaneous interaction.
p250
PACT shares characteristics with SR proteins
In order to further verify that p250 is actually the protein encoded by the original cDNA, we utilized a S-labelled D122 nuclear extracts was carried out with 100 mg of lysate and 248, 421, mouse serum, Ab1, Ab2, Ab3 or pre-immune rabbit serum as indicated. After extensive washing, beads were resuspended in 50 mM NaHCO 3 , followed by addition of 1/2 volume of dimethylformamide, with or without the acetylating reagent as indicated. After 30 min at 258C, proteins were resolved on SDS ± PAGE and blotted (a). The blot was subjected to immunoblot analysis with Ab2. p250
PACT is indicated by arrow. The 248 reaction is shown in a longer exposure. (b) Autoradiogram of A showing the presence or absence of p53. (c) Rb is co-immunoprecipitated with anti-PACT and with anti-p53 antibodies. A similar experiment was carried out as in a except that the lystates were not acetylated and the blot was analysed with anti-Rb monoclonal antibodies. Ab1, Ab2, Ab3, preimmune rabbit serum, 421, 248 or mouse serum (as indicated) were used to immunoprecipitate proteins from D122 nuclear extract. Lane 8 shows non-fractionated D122 nuclear extract where total Rb can be seen. The arrow shows the position of Rb protein p53 and Rb bind PACT, a SR protein A Simons et al biochemical procedure for purifying proteins that contain SR regions (Blencowe et al., 1995) . SR proteins have a propensity to precipitate out of solution upon incubation with 20 mM MgCl 2 (Roth et al., 1991) . This precipitate can be re-dissolved using 2 M NaCl and 20 mM EDTA. Indeed, p250 could be quantitatively precipitated from D122 nuclear extracts and resuspended using the high salt, EDTA treatment, (Figure 8 , lanes 3 and 8) suggesting that it is indeed an SR protein as predicted by the cDNA sequence. Further puri®cation of SR proteins with this method can be facilitated by incubation of nuclear extracts with ATP and creatine phosphate, which are used as high energy phosphate donors by cellular factors to phosphorylate serines in the SR region (Blencowe et al., 1995) . Although this treatment had little eect on the MgCl 2 precipitation step, it did aect the ability of p250
PACT to re-dissolve in high salt and EDTA (compare Figure 8 , lane 5 to lane 10). This suggests that PACT may belong to a large group of previously described SR related proteins (Fu, 1995) and that the SR region may be phosphorylated in vitro by existing kinases.
Association of PACT with small nuclear ribonucleoproteins (snRNPs)
Pre-mRNA splicing requires the participation of spliceosomal U snRNPs, which include the U snRNAs, the common Sm antigens and several speci®c snRNP proteins. Several non-snRNP spliceosomal proteins are also required for splicing (reviewed in Moore et al., 1993) . Among the non-snRNP splicing factors are the SR proteins which are characterized by serine/arginine rich domains. It has been proposed that the SR proteins play a regulatory role in pre-mRNA splicing; i.e., in splice site selection and in alternative splicing (Zahler et al., 1992 (Zahler et al., , 1993 Fu, 1995) . Thus, the localization of PACT to nuclear speckles along with the existence of an SR region in the protein, suggests that PACT may play a role in pre-mRNA splicing. In order to determine if p250
PACT is physically associated with cellular splicing components, we immunoprecipitated PACT from HeLa cell nuclear extract and performed immunoblot analysis with two antibodies that recognize snRNP proteins. The reactions were carried out at 150 mM and 500 mM NaCl conditions. Figure 9a shows that the Sm snRNP antigens were present in anti-PACT immunocomplexes, even at high salt concentration, whereas U1-70K protein was not (Figure 9b ).
Discussion
Characterization of PACT
We have isolated a p53 binding protein, PACT, with several characteristics that may shed light on novel p53 functions. Using a similar methodology, we and another group independently isolated portions of PACT as a p53 binding protein and as an Rb binding protein (Sakai et al., 1995) , respectively. The C' terminal portion of the protein was isolated on the basis of its ability to bind p53, while the N' terminal portion was isolated as the Rb binding entity.
PACT can bind both cellular p53 and Rb proteins and associates with the wild type, but not mutant recombinant p53 protein. One mutant (codon 270 arg?cys), is a protein that is de®cient in DNA binding, but is otherwise similar to wt p53, in that it is recognized by the wt speci®c PAb 246 antibody. Another mutant p53 used, M11, carries two separate aa substitutions (Wolf et al., 1985) , is de®cient in DNA binding, is not recognized by PAb 246, but is recognized by mutant speci®c PAb 240. Thus, recombinant PACT could bind two dierent recombinant wt p53 proteins, produced in two dierent systems, but could not bind either of the mutant forms of the recombinant p53 proteins. Also, PACT can interfere with p53 speci®c DNA binding activity, PACT can be puri®ed by a biochemical procedure speci®c for SR proteins. A procedure for enrichment of S). Samples from various steps of puri®cation were subjected to acetylation and immunoblot analysis with PAb2. Nuclear extracts (lanes 1 and 6) were incubated at 308C with (lanes 6 ± 10) or without (lanes 1 ± 5) ATP and creatine phosphate. MgCl 2 was added to 20 mM and extracts were centrifuged following a 30 min incubation on ice. p250
PACT was present mainly in the pellets (lanes 3 and 8) and not in the supernatants (lanes 2 and 7). The pellets were resuspended in 2 M NaCl and 20 mM EDTA, kept on ice for 1 h, and centrifuged. Without the phosphorylation substrates, p250
PACT was divided equally between the supernatant and the pellet (lanes 4 and 5). All of the protein was found in the supernatant when ATP and creatine phosphate were added (lanes 9 and 10) . Lane 1 contains unfractionated nuclear extract. The Sm doublet was bound to PACT immunocomplexes even at 500 mM salt conditions. U1-70K was not precipitated with PACT p53 and Rb bind PACT, a SR protein A Simons et al which may be taken as a measure of PACT's ability to eciently compete with the speci®c DNA binding oligonucleotide for p53 binding.
We took advantage of the presence of two separate predicted protein domains in PACT to biochemically characterize the protein and to con®rm that the protein recognized by our antibodies does indeed originate from the PACT cDNA sequence. One is the well documented SR domain, which causes aggregation of SR containing proteins in 20 mM MgCl 2 (Zahler et al., 1992) . p250
PACT does indeed precipitate from nuclear extracts under these conditions. Another domain is an unusual lysine rich region at the C' terminus of PACT. p250
PACT can not be seen on SDS ± PAGE without prior acetylation by an in vitro chemical modi®cation step, but the truncated H69c protein can. This suggests that p250 PACT does indeed have the lysine rich region encoded by the cDNA and that this region is responsible for the odd behaviour of p250
PACT on SDS ± PAGE.
Both domains are positively charged and may undergo functionally signi®cant chemical modifications in vivo. The SR domain is known to be a site in which serines are phosphorylated by a kinase speci®c for this region (Gui et al., 1994a,b) . We have no data, as yet, that the lysine rich region can undergo in vivo modi®cation. However, this domain is reminiscent of the basic N' termini of several histones. Core histones are known to undergo cell cycle dependent acetylation and deacetylation (reviewed in Bradbury, 1992) . These modi®cations may cause a dierential anity of the nucleosomes to DNA, allowing dierential chromatin packaging throughout the cell cycle. The positively charged lysine rich region in PACT is immediately adjacent to the C' terminus, and seems to have relatively low secondary structure (GCG software; data not shown). Upon acetylation, this area becomes neutral and may change its conformation in a way that modi®es the overall functional capabilities of the protein, including p53 binding. The in vitro acetylation reaction used in this study apparently eects all the lysines throughout the protein. Thus, evaulation of the functional role of this interesting region awaits a thorough mutational analysis of the protein.
PACT binding to p53 and Rb: similarities to viral oncoproteins DNA tumor viruses produce oncoproteins that bind and inactivate both p53 and Rb, as bipartate elements (i.e. Ad5 E1A and E1B; HPV E6 and E7) or as single molecules that can bind both suppressor proteins (i.e. SV40 large T antigen; EBNA-5). It is interesting that PACT possesses the ability to bind two dierent tumor suppressor proteins. It is tempting to speculate that this characteristic of PACT may have functional importance. The interaction between PACT and these two tumor suppressor proteins is quite similar in nature to that of the viral oncoproteins. The viral proteins that bind p53 do not bind most mutated forms of p53. In addition, large T binds exclusively to the underphosphorylated form of Rb. Sakai et al. (1995) claim that RBQ1 also preferentially binds to the underphosphorylated, growth suppressive form of Rb and that E1A can disrupt this interaction. The Rb bound to PACT in D122 cells appears as a single band and it appears to be the underphosphorylated p105
Rb form. Furthermore, large T binds Rb and p53 through two separate sites. Rb binds to large T at aa 101 ± 118 (DeCaprio et al., 1988; Ludlow et al., 1989) and p53 binds in a broader area between aa 271 ± 517 (Mole et al., 1987; Schmieg et al., 1988) . One could speculate that the analogies between these interactions point to a role for PACT in regulation of growth control mediated by p53 and Rb. Perhaps viral oncoproteins can subvert this regulation by competition with PACT for p53 and Rb binding. Interestingly, a possible RNA-speci®c cellular function for p53 was originally hinted at through interactions with large T. The p53-large T complex was visualized in electron microscopy in association with hnRNP structures (de Fromental et al., 1986) . Both p53 and large T covalently bind cellular RNA (Samad et al., 1986) . Large T can function as an RNA helicase (Schener et al., 1989) and p53 can eciently inhibit this activity when in excess (Oberosler et al., 1993) . p53 can, in fact bind RNA, alter RNA-RNA interactions and promote annealing of RNA (Obersoler et al., 1993) . If PACT and p53 actually work together in this purported RNA-speci®c activity, the presence of large T or other viral oncoproteins may perturb or subvert this function to support viral growth.
The possible connection between PACT and splicing
Three features of p250PACT suggest that this protein may be connected to the cellular pre-mRNA splicing mechanism. First, the localization of three dierent anti-PACT antibodies to nuclear speckles indicates that PACT is abundant at these sites, where several pre-mRNA splicing components reside (Spector, 1993) . Second, the association of PACT with the Sm antigens in nuclear extracts, as shown by coimmunoprecipitation, suggests that PACT is associated with these splicing factors in the living cells. Third, PACT cDNA encodes an SR region and p250
PACT has biochemical properties similar to known SR proteins (Figure 7 ). Protein splicing factors with an SR rich domain can be classi®ed into two groups: (i) the SR protein family (Zahler et al., 1992) and (ii) the SR protein related polypeptides (Fu, 1995) . Proteins in the former group have a carboxy terminal SR domain, and they are identi®ed by monoclonal antibody (MAb) 104 which recognizes a phosphorylated SR epitope (Roth et al., 1990) . PACT may be a member of the latter group, since its SR domain is present at the amino terminus, and it is not recognized by MAb 104 (data not shown). In addition, we could not identify an RNA binding motif in the PACT sequence. Such a motif is common to the SR protein family but is absent from some of the SR protein related polypeptides. For example, it is absent from the small subunit of U2 auxiliary factor (U2AF35) (Zhang et al., 1992) . Proteins of both groups play important roles in spliceosome assembly and splicing regulation, partly due to protein-protein interactions involving their SR domain. Whether or not PACT is actually a splicing related factor remains to be seen.
Two reported connections between tumor suppressor proteins and the pre-mRNA splicing machinery exist.
The ®rst concerns the Wilm's tumor predisposition gene product, WT1. WT1 has four dierent alternatively spliced forms. Two of these forms co-localize with known splicing factors in nuclear speckles (Larsson et al., 1995) . WT1 can be immunoprecipitated with antisera to these factors. It was also shown that the dierent forms shuttle between transcriptional regions and splicing regions in the nucleus. In the second report it was shown that the amino terminal portion of the Rb protein can interact with a novel 84 kDa protein that also co-localizes to nuclear speckles (Durfee et al., 1994) . These two ®ndings, plus the PACT interaction with p53 and Rb, points to a possible connection between tumor suppressor proteins and mRNA processing. Future studies must concentrate on characterization of the eects of PACT on splicing. Also, it will be interesting to see whether tumor suppressor proteins can directly in¯uence this pre-mRNA splicing.
Materials and methods
cDNA libraries
The original library used was derived from Balb/C adult mouse testes cloned into lgt11 (Clonetech). Further plaques were isolated from this library and a mouse testes cDNA library cloned into lgt10 that was a kind gift from Dr Uri Nir Bar Ilan University, Ramant Gan, Israel.
Library screening
The wild type p53 sequence was expressed from the pET-3D vector (Novagen) as previously described (ShohatFoord et al., 1991) . Induction was carried out with 0.4 mM IPTG in BL21 (DE3) bacteria at 308C overnight. Soluble protein was immunoanity puri®ed by a standard procedure (Harlow et al., 1988) . PAb-421 was puri®ed on protein A Sepharose and covalently crosslinked to Sepharose 4B beads (Pharmacia) using the CNBr method (Harlow and Lane, 1988) . After passing the protein over the 421 column three times, proteins were eluted by applying 100 mM triethanolamine pH 11. Fractions were collected into 1/10 volume of 1 M NaH 2 PO 4 pH 6.8 and dialyzed overnight against PBS at 48C. This partially puri®ed protein was iodinated using 1 mCi of [Na 125 I] (Amersham) for 100 mg of protein according to the cloramine T procedure (Harlow and Lane, 1988) . The cDNA expression library was plated out at 5610 4 pfu/200 mm LB agarose plate on a bacterial lawn of Y1090r-bacteria. 1610 6 plaques were grown for 3.5 h at 428C. For protein expression, plates were overlayed with nitrocellulose ®lters (Schleicher and Schuell) previously soaked in 10 mM IPTG, and incubated for an additional 3.5 h. Filters were removed and soaked in binding buer (25 mM HEPES pH 7.5, 3 mM MgCl 2 , 4 mM KCl, 1 mM DTT) containing 6M guanidine HCl for denaturation. All subsequent handling was at 48C with gentle shaking. Denatured proteins were allowed to refold using stepwise dilution of the guanidine HCl with fresh binding buer at half volume steps every 5 min until the concentration was less than 0.1 M guanidine HCl. Filters were then blocked in binding buer with 5% milk for 30 min and then overnight in binding buer with 1% milk and 0.1 mg/ml [ 125 I]p53. Filters were washed extensively with PBS+ 0.3% Tween-20 for 3 h at room temperature and exposed to X-ray ®lm.
When the library was screened with a DNA probe standard procedures were used (Maniatis et al., 1982) . Final veri®cation of plaque puri®cation was carried out by PCR ampli®cation of the insert using speci®c primers for lgt11 or lgt10. Sequencing reactions were carried out on an Applied Biosystems 373A analyser.
RNA Northern analysis
Total RNA was isolated from Balb/C mouse tissues using the guanidine thiocyanate method (Chirgwin et al., 1979) and 50 mg/lane was subjected to standard Northern Blot analysis (Maniatis et al., 1982) .
In vitro binding assay
A 3441 bp EcoRI to BglII DNA fragment encoding nucleotides 1299 ± 4740 from the PACT sequence was subcloned into pET20b vector (Novagen) such that both the 3' and 5' were in frame to the vectors initiating methionine and the C' terminal His Tag. This vector was transfected into pLysS BL21 (DE3) bacteria and grown to OD 580 0.6 when IPTG was added to 0.4 mM. Induction was carried out at 308C overnight. Harvested cells were resuspended in sonication buer (50 mM NaHPO 4 pH 8, 300 mM NaCl) at ®ve volumes per gram weight and sonicated on ice with 1 min bursts. After centrifugation at 10 000 g for 20 min, the supernatant was incubated with an equilibrated 50% slurry of Ni-NTA resin (Qiagen) for 60 min on ice with stirring. Resin was loaded onto a column and washed extensively with sonication buer and then wash buer (50 mM NaHPO 4 , 300 mM NaCl, 10% glycerol, pH 6). Protein was eluted with a 30 ml gradient of 0 ± 0.5 M imidazole in wash buer and analysed on SDS ± PAGE.
1 mg of this protein was incubated with 1 mg of puri®ed bacculovirus wild type or mutant p53 (kind gift from Prof Moshe Oren) at 308C for 15 min. 1 ml of ice cold NETN (20 mM Tris pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% NP40) was added together with 20 ml of 50% NiNTA resin and incubated at 48C with tumbling for 1 h. Resin was washed 36 with NETN containing 40 mM imidazole. Proteins were separated on SDS ± PAGE and blotted onto nitrocellulose. Detection of bound p53 was carried out with PAb-421 at a 1 : 200 dilution in PBST followed by a 1 : 20 000 dilution of sheep anti-mouse horseradish peroxidase (HRP) antibody. ECL detection was carried out according to manufacturers instructions (Amersham).
Gel retardation assay
DNA binding assay was carried out as described (Wolkowicz et al., 1995) .
Antibodies and recombinant PACT proteins
Polyclonal anti-PACT antisera were elicted by immunizing rabbits with recombinant proteins. Ab1 was against a recombinant GST fusion protein made by subcloning aa 1220 ± 1562 into the pGEX1 vector (Pharmacia). Ab2 and Ab3 were fusion proteins produced by subcloning aa 826 ± 1319 (Ab2) or aa 609 ± 833 (Ab3) into pET 20b (Novagen). Antisera were anity puri®ed against the PACT His Tag 436 ± 1584 aa recombinant protein immobilized on Sepharose and released with 0.1 M ammonium hydroxide. Preimmune sera were puri®ed by binding to protein ASepharose and release with 0.1 M ammonium hydroxide.
Immuno¯uorescent staining
Immuno¯uorescent staining was carried out as described (Harlow and Lane, 1988) . Brie¯y, adherent cells were grown on cover slips for 24 h and ®xed with 4% paraformaldehyde for 30 min followed by permeabilizap53 and Rb bind PACT, a SR protein A Simons et al tion with 0.2% triton for 10 min. After washing with PBS, antibodies were added for 30 min at dilutions up to 1 : 200 in PBS. Coverslips were washed and FITC conjugated antirabbit antibodies were added at 10 mg/ml in PBS for 30 min. Extensive washing was followed by¯uorescent microscopy.
Acetylation
Acetylation (Bayer EA, Ehrlich-Rogozinski S and Wilchek M, unpublished procedure) was carried out by incubating nuclear extract or cytoplasmic fractions (Dignam et al., 1983) with 1/2 volume of 50 mM NaHCO 3 pH 8 and 1/2 volume of fresh 10 mg/ml acetic acid N' hydroxy succinamide ester (Sigma) dissolved in N, N-dimethylformamide. The reaction was at 258C for 30 min. SDS ± PAGE sample buer was then added and proteins were separated on 8% acrylamide gels. Western detection of acetylated proteins was carried out as described above.
Immunoprecipitation
Immunoprecipitation was carried out at 48C using 100 mg of nuclear extract for 4 h in 1 ml of NETN containing 0.5 mM DTT and 0.5 mM PMSF together with relevant antibody. Protein A Sepharose was added for an additional hour and complexes were washed 36 with NETN 200 mM NaCl with 0.5 mM DTT. When PACT was to be visualized on gels, beads were resuspended in 50 mM NaHCO 3 and acetylated as above. Otherwise, proteins present in the immunocomplex were analysed on immunoblots with appropriate antibodies.
SR protein puri®cation
Puri®cation of SR containing proteins was carried out as described (Blencowe et al., 1995) , using nuclear extract prepared from D122 lung carcinoma cells according to Dignam et al. (1983) .
GenBank Accession Numbers
GenBank Accession Numbers The GenBank accession number of the PACT cDNA used in this article is U28789. The dbEST databank accession number for the EST fragment displayed here is R85735.
